AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 175 filers reported holding AMYLYX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,348,623 | -83.9% | 73,655 | -81.0% | 0.26% | -81.1% |
| Q2 2023 | $8,354,277 | +17.5% | 387,310 | +59.8% | 1.39% | +1.9% |
| Q1 2023 | $7,112,016 | +21.9% | 242,400 | +53.5% | 1.37% | +21.1% |
| Q4 2022 | $5,836,253 | +0.9% | 157,950 | -23.1% | 1.13% | -0.9% |
| Q3 2022 | $5,782,000 | – | 205,400 | – | 1.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 2,756,050 | $35,415,000 | 3.44% |
| Boxer Capital, LLC | 2,200,000 | $28,270,000 | 1.45% |
| Alpha Wave Global, LP | 617,220 | $7,931,000 | 0.72% |
| Ikarian Capital, LLC | 396,654 | $5,097,000 | 0.67% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 768,603 | $9,877,000 | 0.58% |
| Ikarian Capital, LLC | 250,000 | $3,213,000 | 0.42% |
| 683 Capital Management, LLC | 677,714 | $7,685,000 | 0.41% |
| Perceptive Advisors | 1,474,107 | $18,942,000 | 0.38% |
| VIKING GLOBAL INVESTORS LP | 7,170,536 | $92,141,000 | 0.37% |
| Rock Springs Capital Management LP | 998,307 | $12,828,000 | 0.32% |